THE SHORT ANSWER
Does Medicaid Cover Wegovy?
Always Verify Coverage With Your State Medicaid Program
Medicaid coverage changes frequently. States can modify, add, or remove coverage at any time due to budget constraints or policy changes. Before assuming you have (or don't have) coverage, call your state Medicaid program directly to verify current Wegovy coverage status.
Coverage Varies Dramatically by State
State Medicaid programs covering GLP-1s like Wegovy for weight loss: only 13 states (as of January 2026). Most state Medicaid programs either don't cover anti-obesity medications at all, or are actively ending coverage due to budget constraints.[1][2][9]
Unlike commercial insurance or Medicare, Medicaid coverage for weight loss medications is entirely optional for states. Federal law doesn't require states to cover anti-obesity drugs, which means:
- Only about a quarter of states (13 states (as of January 2026)) cover GLP-1 (glucagon-like peptide-1) weight loss medications like Wegovy[1][2][9]
- Coverage is shrinking—several states are ending or restricting coverage in 2025-2026[8]
- Even in states with coverage, strict prior authorization requirements apply—your doctor must get approval before the medication is covered[13]
- Diabetes coverage is different—GLP-1 medications are typically covered for type 2 diabetes in all states[10]
Bottom line: If you have Medicaid, your coverage depends entirely on your state's policies. Check with your state Medicaid program directly to confirm whether Wegovy is covered for weight loss.
For a complete overview of getting Wegovy covered regardless of insurer, see our full coverage guide.
STATE-BY-STATE MEDICAID COVERAGE
Which States Cover Wegovy?
Based on the latest KFF (Kaiser Family Foundation) Medicaid report and state policy documents, here's which states cover Wegovy or other GLP-1s for obesity under their Medicaid programs:[1][2]
Coverage Is Changing Rapidly
State Medicaid coverage for weight loss drugs is in flux. Several states have recently ended or announced plans to end coverage. Always verify with your state Medicaid program before assuming coverage.
States With Medicaid Wegovy Coverage
| State | Coverage Status | Key Details | Last Verified |
|---|---|---|---|
| California (Medi-Cal) | Ended 1/1/2026 | Coverage ends January 2026; PA required until then[3] | Nov 2025 |
| Connecticut | Uncertain | Gov. Lamont proposed ending coverage due to $290M deficit; verify status[25] | Jan 2026 |
| Delaware | Ended 1/1/2026 | Coverage ended Jan 1, 2026; shifted to weight management program[30] | Jan 2026 |
| Kansas | CVD Only | Requires BMI (body mass index) ≥27 + established cardiovascular disease (heart attack, stroke, PAD); NOT covered for obesity alone[31] | Jan 2026 |
| Massachusetts | Covered (Zepbound preferred) | Adults switched to Zepbound as preferred Jan 2025; Wegovy for ages 12-17 only[4][20] | Jan 2026 |
| Michigan | Restricting 1/1/2026 | Effective Jan 2026: morbid obesity only + must fail other interventions first[21] | Jan 2026 |
| Minnesota | Covered | PA required; may need to try other meds first | Nov 2025 |
| Mississippi | Covered | PA required; progress milestones required[1] | Nov 2025 |
| New York | Covered | PA required; may need to try other meds first | Nov 2025 |
| North Carolina | Covered (Reinstated) | Coverage reinstated Dec 12, 2025 per Governor's directive[5][19] | Jan 2026 |
| Pennsylvania | Ended 1/1/2026 | Adults 21+ losing coverage Jan 2026; under-21 still covered via EPSDT (Early and Periodic Screening, Diagnostic, and Treatment)[23] | Jan 2026 |
| Vermont | MACE Only | Wegovy covered for MACE (major adverse cardiovascular events—heart attack, stroke) reduction only, NOT obesity standalone[24] | Jan 2026 |
| Wisconsin | Covered | PA required; BMI and documentation criteria | Nov 2025 |
States With Partial or Restricted Coverage
| State | Status | Notes | Last Verified |
|---|---|---|---|
| Texas | Partial | Restricted coverage; details vary by managed care plan | Nov 2025 |
| Washington | Partial | May cover for select populations; PA required | Nov 2025 |
| Arizona | Partial | Coverage varies by MCO (managed care organization); check your specific plan | Nov 2025 |
Note: Coverage status as of November 2025. States frequently change policies—always verify directly with your Medicaid program.
How to Check Your State's Coverage
Call Script for Medicaid
"Hi, I'm calling to check prescription drug coverage under my Medicaid plan. My member ID is [NUMBER]. I need to know:
- Is Wegovy (semaglutide) covered for chronic weight management?
- What are the prior authorization requirements?
- What BMI and documentation do I need?
- Is there step therapy—do I need to try other medications first?
- Can you send me the coverage criteria in writing?"
2025-2026 MEDICAID CHANGES
States Ending Coverage
Due to budget pressures and the high cost of GLP-1 medications, several states have announced they're ending or restricting Medicaid coverage for weight loss drugs:
California (Medi-Cal) Ended Coverage January 1, 2026
Medi-Cal stopped covering GLP-1s for weight loss on January 1, 2026. This includes Wegovy, Zepbound, and Saxenda when prescribed for obesity.[3][14]
Coverage continues for:
- Type 2 diabetes (Ozempic, Mounjaro)
- Cardiovascular risk reduction
- Other FDA-approved non-weight-loss indications
If you're affected: Talk to your doctor about diagnosis codes that may maintain coverage, or explore self-pay options (Wegovy is not on Novo Nordisk’s Patient Assistance Program list).
✅ North Carolina Reinstated Coverage December 12, 2025
UPDATE: NC Medicaid briefly ended GLP-1 coverage for obesity on October 1, 2025, but coverage was reinstated on December 12, 2025 per the Governor's directive.[5][19]
Coverage has been restored to pre-October 2025 levels. Prior authorization is still required.
Michigan Restricting Coverage January 1, 2026
Effective January 1, 2026, Michigan Medicaid will restrict Wegovy, Zepbound, and Saxenda to patients classified as morbidly obese who have failed all other weight-loss interventions and are using the medication to avoid bariatric surgery.[21]
Current prior authorizations will be honored for their 6-month duration, but new criteria apply at renewal. Coverage for diabetes indications (Ozempic, Mounjaro) is unchanged.
Pennsylvania Ending Adult Coverage January 1, 2026
Pennsylvania Medicaid will stop covering GLP-1s for weight loss for adults 21 and older starting January 1, 2026. Children and young adults under 21 may still receive coverage under federal EPSDT (Early and Periodic Screening) requirements.[23]
Adults prescribed GLP-1s for other conditions (diabetes, cardiovascular disease) may still qualify if they meet PA requirements.
New Hampshire Ending Coverage January 1, 2026
NH Medicaid will no longer cover GLP-1 medications when prescribed solely for weight loss starting January 1, 2026. Governor Ayotte cited cost sustainability as the primary driver.[26]
South Carolina Ending Coverage January 1, 2026
South Carolina will stop covering GLP-1 drugs for weight loss on January 1, 2026, reversing a year-old policy. Coverage continues for Type 2 diabetes.[27]
Delaware Ended Coverage January 1, 2026
Delaware Medicaid ended GLP-1 coverage for weight loss effective January 1, 2026. Coverage shifted to a weight management program through Vida providers.[30]
Why States Are Cutting Coverage
State Medicaid programs are facing unsustainable costs from GLP-1 medications:
- Wegovy costs $1,349/month at list price—multiplied across thousands of beneficiaries[6]
- Medicaid drug spending on GLP-1s has increased dramatically since 2020[1]
- Budget constraints force states to make difficult coverage decisions
- Unlike commercial insurance, states can't spread costs across a broader risk pool
According to KFF, states that do cover GLP-1s for obesity report significant budget impacts, leading several to reconsider or restrict coverage going forward.[1]
🗓️ November 2025: Lower GLP-1 Prices and the BALANCE Model
On November 6, 2025, the Trump administration announced agreements with Eli Lilly and Novo Nordisk to lower GLP-1 prices, including for state Medicaid programs.[15][16] CMS's BALANCE Model has a Medicaid track: Voluntary for states, which can join between May 2026 and January 1, 2027; no participating state has been confirmed.
What this means:
- Lower prices could ease the cost burden that's been driving coverage cuts
- States that cut coverage (like CA) may reconsider
Important: Joining is up to each state, and no state has been confirmed as a participant. Check with your state Medicaid program.
MEDICAID CRITERIA FOR WEGOVY
Prior Authorization Requirements
In states that cover Wegovy through Medicaid, prior authorization is almost always required. Medicaid PA requirements are often stricter than commercial insurance:
Typical Medicaid PA Criteria
| Requirement | Typical Medicaid | Notes |
|---|---|---|
| BMI Threshold | ≥30, or ≥27 with a weight-related health condition | Some states require higher BMI (≥35) |
| Qualifying Health Conditions | High blood pressure, type 2 diabetes, high cholesterol, sleep apnea, heart disease | Must be documented in your medical records |
| Lifestyle Documentation | 6+ months of diet/exercise attempts | Medicaid often enforces this more strictly than private insurance |
| Try Other Meds First | Often required | May need to try phentermine or other weight loss medications first |
| Progress Requirements | 5% weight loss for renewal | Some states require you to show ongoing progress |
| Initial Approval Length | 3-6 months typical | You may need to reapply for continued coverage |
Documentation Checklist
Before your doctor submits a Medicaid PA request, ensure these are documented:
Required Documentation
- Current height and weight (measured within the last 30 days)
- BMI calculation documented by your doctor
- Diagnosis of obesity or weight-related conditions—your doctor should have these on file:
- Obesity (mild, moderate, or severe)
- High blood pressure
- Type 2 diabetes
- High cholesterol
- Sleep apnea
- 6+ months of diet and exercise efforts—notes from doctor visits, dietitian referrals, or gym membership records
- Previous weight loss attempts—what you've tried before and why it didn't work long-term
Documentation That Strengthens Your Case
- Weight history showing obesity over the past 2-3 years
- Records of past weight loss medications you've tried (and the results)
- Recent lab work—blood sugar (A1C, a 3-month blood sugar average), cholesterol panel
- Sleep study results if you've been tested for sleep apnea
- Notes about how your weight affects your daily life (difficulty walking, joint pain, etc.)
- Any hospital or ER visits related to weight complications
For complete PA preparation guidance, see our Wegovy prior authorization guide.
Your GLP-1 coverage,
denied approved
If Medicaid denies your Wegovy, Honest Care can help you build a strong appeal with evidence-backed documentation.
Denied by Medicaid?
Get Help NowALTERNATIVE OPTIONS
If Your State Doesn't Cover Wegovy
If your state Medicaid program doesn't cover Wegovy for weight loss, you still have options:
Check for Alternative Diagnosis Coverage
Note: Zepbound (not Wegovy) was FDA-approved for obstructive sleep apnea in December 2024. However, Wegovy may still be covered for cardiovascular risk reduction (MACE) in adults with established cardiovascular disease and either obesity or overweight—even if weight loss is excluded.[28]
- Ask your doctor if you qualify for the cardiovascular indication
- If you have sleep apnea, ask about Zepbound instead—it has FDA approval for that condition
- Some states cover Wegovy for MACE even when they exclude obesity
Explore Patient Assistance Programs
Novo Nordisk offers patient assistance for qualifying individuals:
- Important: Wegovy is NOT covered by Novo Nordisk's Patient Assistance Program (PAP). PAP only covers diabetes medications like Ozempic.[29]
- Wegovy Savings Offer—for patients with commercial insurance, pay as little as $25 (max savings $100 per 1-month fill)
- Not for Medicaid patients—federal/state program enrollees are not eligible for savings offers
See our Wegovy cost guide for details.
Consider Cash-Pay Options
While expensive, cash-pay may be an option for some patients:
- NovoCare Pharmacy—self-pay: $349/month ($399 for Wegovy HD 7.2 mg) (reduced from $499 after Nov 2025 Trump deal); If you have government insurance, ask NovoCare whether you can use self-pay pricing[11][22]
- Compounding pharmacies—may offer lower-cost alternatives (discuss with your doctor)
- Cost-sharing programs—some community health centers offer sliding-scale pricing
Learn more at our Wegovy cost guide.
Explore Other Covered Medications
Your Medicaid may cover other weight loss medications:
- Phentermine—widely covered, much lower cost
- Contrave—covered by some state Medicaid programs
- Qsymia—less commonly covered, but worth checking
If Coverage Recently Ended
If you were previously on Wegovy and your state ended coverage (like California, Pennsylvania, or Delaware), talk to your doctor about:
- Switching to a different weight loss medication that's still covered
- Whether other health conditions (diabetes, heart disease risk) might still qualify for coverage
- Checking if you qualify for coverage under a non-weight-loss indication (MACE, diabetes)
- Appealing if you believe coverage should continue based on your medical situation
MEDICAID WEGOVY COVERAGE
Frequently Asked Questions
It depends entirely on your state. State Medicaid programs covering GLP-1s for weight loss: 13 states (as of January 2026). Most states either don't cover anti-obesity medications at all, or are actively ending coverage due to budget constraints. Medicaid coverage for GLP-1 medications used to treat type 2 diabetes is much more widespread.
As of January 2026, states with some Medicaid coverage include: Massachusetts (Zepbound preferred for adults), Minnesota, Mississippi, New York, North Carolina (reinstated Dec 2025), and Wisconsin. Ended/ending coverage Jan 1, 2026: California, Delaware, Pennsylvania (adults 21+), New Hampshire, South Carolina. Restricting: Michigan (morbid obesity only). Uncertain: Connecticut (proposed ending). CVD indication only (not obesity): Kansas and Vermont. Texas, Washington, and Arizona have partial coverage. Always verify with your state Medicaid program.
California's 2025-26 state budget eliminated Medi-Cal coverage for GLP-1 weight loss medications (Wegovy, Zepbound, Saxenda) effective January 1, 2026. The decision was driven by budget constraints—these medications cost about $1,349/month per patient at Wegovy's list price, which became too expensive for the state program to sustain. Coverage will continue for diabetes, heart disease risk reduction, and other FDA-approved uses.
Typical requirements include: BMI of 30 or higher (or 27+ with a weight-related health condition like high blood pressure, type 2 diabetes, high cholesterol, or sleep apnea), 6+ months of documented diet and exercise efforts, and often a requirement to try other weight loss medications first. Some states also require ongoing weight loss (at least 5%) for continued coverage. Requirements vary by state—ask for your state's specific criteria in writing.
If your state doesn't cover Wegovy for weight loss, you have options: (1) Ask if cardiovascular risk reduction (MACE) coverage applies—Wegovy is FDA-approved for reducing heart attack/stroke risk in adults with established cardiovascular disease and either obesity or overweight; (2) Consider NovoCare Pharmacy cash-pay at $349/month ($399 for Wegovy HD 7.2 mg); (3) Ask your doctor about other covered weight loss medications like phentermine or Contrave. Note: Wegovy is NOT covered by Novo Nordisk's Patient Assistance Program (PAP covers diabetes meds only). For sleep apnea, ask about Zepbound—it has FDA approval for that condition.
Coverage for diabetes is different. Wegovy (semaglutide) is approved for weight loss. For type 2 diabetes, GLP-1 options include Ozempic (semaglutide, same active ingredient as Wegovy) and Mounjaro (tirzepatide, different drug). These diabetes medications are generally covered by Medicaid in all states when prescribed for diabetes. If you have both obesity and type 2 diabetes, your doctor may be able to prescribe a GLP-1 for your diabetes indication instead.
Medicaid appeal processes vary by state. Medicaid health plan: appeal within 60 days of the denial notice; the plan decides within 30 days (72 hours if urgent); then you can ask for a state fair hearing (your state allows 90–120 days). Fee-for-service Medicaid: ask for a fair hearing within your state’s deadline (no more than 90 days). Request your denial letter in writing with the specific reason for denial. Then gather documents that address that reason (a letter from your doctor explaining medical necessity, your weight records, documentation of diet/exercise efforts). At a fair hearing you can present your case to a state hearing officer. Check your denial notice for your exact deadlines.
Possibly, but not immediately. In November 2025, the Trump administration announced agreements to lower GLP-1 prices, including for state Medicaid programs.[15][16] CMS's BALANCE Model Medicaid track: Voluntary for states, which can join between May 2026 and January 1, 2027; no participating state has been confirmed. States that cut coverage due to cost (like California) may reconsider. Each state must choose to join and update its coverage policies, so check with your state Medicaid program for changes.
YOUR PATH FORWARD
What's Next
Wegovy Coverage: Other Insurance Options
Coverage varies significantly by program type. See our guides:
- Medicare — basic Part D coverage excludes weight loss; the Medicare GLP-1 Bridge (outside Part D) covers Wegovy (with conditions)
- TRICARE — Covers with BMI ≥30 and documented comorbidity
- ACA Marketplace — Very rare coverage; ~1% of plans
- Blue Cross Blue Shield — Major 2026 coverage restrictions
- Aetna — Most plans cover with prior authorization
Other GLP-1 Medications on Medicaid
Medicaid coverage varies by state and medication. Compare your options:
Your GLP-1 coverage,
denied approved
✓ Free Templates✓ Premium Support Available
I was denied coverage for...
Get startedReferences
- Kaiser Family Foundation. (2024). "Medicaid Coverage of and Spending on GLP-1s." Updated November 2024. Confirms 13 state Medicaid programs cover GLP-1s for obesity. kff.org
- STAT News. (2024). "More state Medicaid programs consider covering GLP-1 drugs." October 23, 2024. Confirms 13 state Medicaid programs cover GLP-1s for obesity. statnews.com
- California Department of Health Care Services. (2025). "State Budget Updates: Medi-Cal Rx Coverage Changes Effective January 2026." medi-calrx.dhcs.ca.gov
- UnitedHealthcare. (2025). "Zepbound and phentermine added to preferred drug list." Massachusetts Medicaid (UHC Senior Care Options/One Care). January 1, 2025. Confirms Zepbound replaced Wegovy/Saxenda as preferred. uhcprovider.com
- NC Department of Health and Human Services. (2025). "NC Medicaid to Change Coverage for GLP-1 Weight Management Medications." September 5, 2025. Coverage ending October 1, 2025 due to funding shortfalls. medicaid.ncdhhs.gov
- SingleCare. (2025). "Does Medicaid Cover Wegovy for Weight Loss?" Updated October 2025. singlecare.com
- GoodRx. (2025). "Does Medicaid Cover Ozempic, Wegovy, and Other GLP-1 Medications?" Updated August 2025. goodrx.com
- KFF Health News. (2025). "As Insurers Struggle With GLP-1 Drug Costs, Some Seek To Wean Patients Off." September 4, 2025. kffhealthnews.org
- National Conference of State Legislatures (NCSL). (2025). "GLP-1 Medications for Obesity: A Growing Challenge for States." October 2025. Confirms 13 states offer Medicaid coverage. ncsl.org
- National Association of Medicaid Directors (NAMD). (2025). "Optional Not Mandatory: NAMD's Recommendations on Anti-Obesity Medication Coverage." February 2025. medicaiddirectors.org
- Novo Nordisk. (2025). "Wegovy Coverage and Savings." NovoCare Pharmacy self-pay: $349/month for all doses (reduced from $499 after Nov 2025 deal). www.wegovy.com
- NovoCare. (2025). "Wegovy Savings Offer Program." Savings for patients with commercial insurance (not Medicaid/Medicare). Note: Wegovy is NOT covered by Novo Nordisk's Patient Assistance Program. novocare.com
- Novo Nordisk. (2025). "Wegovy Prior Authorization Resource Guide." PA criteria including BMI thresholds and documentation requirements. www.wegovy.com
- California Medical Association. (2025). "DHCS details new Medi-Cal Rx policy changes effective January 2026." October 16, 2025. cmadocs.org
- NCPA. (November 11, 2025). "About the Trump, Eli Lilly, Novo Nordisk deals on GLP-1 prices." ncpa.org
- Axios. (November 6, 2025). "Trump announces Medicare coverage of weight-loss drugs." Includes Medicaid pricing details. axios.com
- AARP. (November 2025). "When Will the Cost of GLP-1 Weight Loss Drugs Go Down?" aarp.org
- CBS News. (November 6, 2025). "Trump announces deal to lower weight loss drug prices in some cases." cbsnews.com
- NC Medicaid. (December 19, 2025). "NC Medicaid to Reinstitute Coverage of GLP-1s for Weight Management." Coverage reinstated per Governor's directive effective December 12, 2025. medicaid.ncdhhs.gov
- Massachusetts Executive Office of Health and Human Services. (October 2024). "The Prescriber e-Letter, Volume 14, Issue 3." Adults switched from Wegovy to Zepbound as preferred for weight management effective January 1, 2025. mass.gov
- Bridge Michigan. (October 2025). "Michigan cuts off weight-loss drugs for most Medicaid patients, saving $240M." Restricting to morbidly obese only effective January 1, 2026. bridgemi.com
- Fierce Pharma. (November 2025). "Novo unveils newly reduced self-pay prices for Wegovy, Ozempic after White House deal." All doses now $349/month, down from $499. fiercepharma.com
- Spotlight PA. (December 2025). "Pennsylvania restricts Medicaid coverage for GLP-1 drugs." Adults 21+ losing coverage Jan 1, 2026. spotlightpa.org
- Stateline. (November 2025). "States retreat from covering drugs for weight loss." Vermont covers Wegovy for MACE only, not obesity standalone. stateline.org
- CT Mirror. (March 2025). "People call GLP-1s life-changing. CT says it can't afford them." Gov. Lamont proposed ending coverage due to $290M Medicaid deficit. ctmirror.org
- New Hampshire Bulletin. (December 2025). "Medicaid to stop covering weight-loss drugs for obesity in New Hampshire." Ending Jan 1, 2026. newhampshirebulletin.com
- SC Daily Gazette. (November 2025). "SC Medicaid program to stop covering expensive weight loss drugs for obesity." Ending Jan 1, 2026, reversing year-old policy. scdailygazette.com
- FDA. (December 2024). "FDA Approves First Medication for Obstructive Sleep Apnea." Zepbound (tirzepatide), not Wegovy, approved for OSA. fda.gov
- NovoCare. (2025). "Patient Assistance Program (PAP)." PAP covers diabetes medications only; Wegovy/Saxenda are excluded. novocare.com
- Delaware Department of Human Resources. (December 2025). "Coverage of GLP-1 for Weight Loss." Coverage ended Jan 1, 2026; shifted to weight management program. dhr.delaware.gov
- Kansas Department of Health and Environment (KDHE). (2025). "Anti-Obesity Medications Prior Authorization Form." KanCare Medicaid criteria require BMI ≥27 + established cardiovascular disease for adults. kdhe.ks.gov
Last updated October 6, 2026 · Key facts verified October 5, 2026
Disclaimer
The information on this page is for educational and informational purposes only and is not intended as medical advice. Honest Care does not provide medical diagnosis, treatment, or individualized recommendations. Always seek the advice of your physician or other qualified healthcare professional regarding any medical condition or treatment.
While this content has been reviewed for accuracy and balance, new evidence may emerge after publication. Drug availability, indications, and insurance coverage can change over time. Honest Care makes no warranties as to completeness or currentness of the information and is not responsible for decisions made based on this content.